Poor gut health connected to severe COVID-19
People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems.
People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems.
Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder affecting 10 – 20 per cent of people. Abdominal pain, bloating and altered bowel habit significantly affect patients’ quality… read more.
Two years after recommendations, only a small percentage have been tested. A Brief Report appearing in the American Journal of Preventive Medicine looks at testing rates for Hepatitis C virus… read more.
The genetic and clinical heterogeneity of IBD means translational research has a key role to play. A session dedicated to translational and basic science at UEG Week 2019… read more.
An oral abstract session dedicated to patient-reported outcomes (PROs) in IBD included surveys from France and the Netherlands and from the multi-centre ICONIC study.. Written by Maria Dalby
Dr Maria Abreu (Miami, USA) gives us an overview of implementing disease monitoring and its challenges in clinical practice Written by Maria Dalby
A subcutaneous formulation of infliximab, known as CT-P13 SC, has been developed with a view to offer greater flexibility and convenience for patients.
In a round-up of randomised controlled studies in IBD at UEG Week 2019 included results from the maintenance phase of the UNIFI study in UC and a phase-3… read more.
Professor Jean-Frédéric Colombel (Icahn School of Medicine at Mount Sinai, New York, USA) opened the symposium with an overview of how treatment targets in UC have evolved from improving… read more.
UEGW 2019, held in Barcelona, Spain, was a very interesting meeting, covering a wide range of hot topics from the world on IBD. The meeting was well-attended with… read more.
Dr Bram Verstockt (Leuven, Belgium) discusses a biopsy study looking at increases NCR+ ILC3 levels in IBD patients on biologic therapy.
IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation…
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.